公开(公告)号：US20170101402A1

公开(公告)日：2017-04-13

申请号：US15315713

申请日：2015-06-01

Applicant: CHDI Foundation, Inc.

Inventor： Celia Dominguez ,  Ignacio Muñoz-Sanjuán ,  Christopher A. Luckhurst ,  Daniel R. Allen ,  Gilles Raphy ,  Roland W. Bürli ,  Perla Breccia ,  Alan F. Haughan ,  Grant Wishart ,  Samantha J. Hughes ,  Rebeca E. Jarvis ,  Huw D. Vater ,  Stephen D. Penrose ,  Michael Wall ,  Andrew J. Stott ,  Elizabeth A. Saville-Stones

IPC: C07D417/04 ,  C07D401/04 ,  C07D403/04 ,  C07C259/08 ,  C07D239/88 ,  C07D277/60 ,  C07D239/70 ,  C07D231/54 ,  C07D231/56

CPC classification number: C07D417/04 ,  C07C259/08 ,  C07D231/54 ,  C07D231/56 ,  C07D239/70 ,  C07D239/74 ,  C07D239/88 ,  C07D275/04 ,  C07D277/60 ,  C07D401/04 ,  C07D403/04

Abstract: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use. The condition or disorder mediated by HDAC comprises a neurodegenerative pathology. Accordingly, also provided is a method of treating a neurodegenerative pathology mediated by HDAC in a subject in need of such a treatment, comprising administering to the subject a therapeutically effective amount of at least one compound, or pharmaceutically acceptable salt thereof, described herein.